SCHEMBL7861891

SCHEMBL7861891

CCC(=O)Oc1c(Br)cc(Br)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.46
THRB P10828 5/20 0.40
ESR1 P03372 2/20 0.39
HIF1A Q16665 2/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ACHE P22303 3/20 0.38
ALOX15 P16050 2/20 0.38
ALOX12 P18054 1/20 0.37
THRA P10827 4/20 0.37
ELANE P08246 1/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL814000 0.82 KMT2A (0.46) HSD17B10ESR1HIF1ARECQLKMT2A
SCHEMBL4641891 0.82 HSD17B10 (0.43) HSD17B10THRBKMT2AALOX15ALOX12
SCHEMBL4021940 0.80 THRA (0.44) HSD17B10THRBRECQLKMT2ASMN1; SMN2
SCHEMBL4642204 0.80 HSD17B10 (0.42) HSD17B10THRBKMT2AALOX15ALOX12
SCHEMBL4641747 0.80 HSD17B10 (0.42) HSD17B10THRBESR1KMT2AALOX15
SCHEMBL4646760 0.78 HSD17B10 (0.41) HSD17B10THRBESR1KMT2AALOX15
SCHEMBL9169212 0.78 HSD17B10 (0.41) HSD17B10THRBKMT2AALOX15THRA
SCHEMBL14142981 0.78 HSD17B10 (0.41) HSD17B10THRBKMT2ASMN1; SMN2ALOX15
SCHEMBL29131729 0.78 KMT2A (0.48) HSD17B10ESR1HIF1ARECQLKMT2A
SCHEMBL4647871 0.77 HSD17B10 (0.40) HSD17B10THRBESR1KMT2AALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11160773-B2 Method for enhancing folding and transport of misfolded glucocerebrosidase THE HOSPITAL FOR SICK CHILDREN (CA) 2021-11-02 US disclosed
US-20200246282-A1 Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase THE HOSPITAL FOR SICK CHILDREN (CA) 2020-08-06 US disclosed
US-10653645-B2 Method for enhancing folding and transport of misfolded glucocerebrosidase THE HOSPITAL FOR SICK CHILDREN (CA) 2020-05-19 US disclosed
US-10028922-B2 Method for enhancing folding and transport of misfolded glucocerebrosidase THE HOSPITAL FOR SICK CHILDREN (CA) 2018-07-24 US disclosed
US-10028922-B2 Method for enhancing folding and transport of misfolded glucocerebrosidase THE HOSPITAL FOR SICK CHILDREN (CA) 2018-07-24 US disclosed
US-20160331701-A1 Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase MCMASTER UNIVERSITY (CA) 2016-11-17 US disclosed
US-20160331701-A1 Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase MCMASTER UNIVERSITY (CA) 2016-11-17 US disclosed
US-9415025-B2 Methods of treating Parkinson's disease THE HOSPITAL FOR SICK CHILDREN (CA) 2016-08-16 US disclosed
US-9415025-B2 Methods of treating Parkinson's disease THE HOSPITAL FOR SICK CHILDREN (CA) 2016-08-16 US disclosed
US-20160113892-A1 Method For Enhancing Folding and Transport of Misfolded Glucocerebrosidase MCMASTER UNIVERSITY (CA) 2016-04-28 US disclosed
US-20130184352-A1 METHOD OF TREATING GAUCHER DISEASE MCMASTER UNIVERSITY (CA) 2013-07-18 US disclosed
US-20130090388-A1 METHOD OF TREATING GAUCHER DISEASE MCMASTER UNIVERSITY (CA) 2013-04-11 US disclosed
US-20130090388-A1 METHOD OF TREATING GAUCHER DISEASE MCMASTER UNIVERSITY (CA) 2013-04-11 US disclosed
US-8124597-B2 Method of treating gaucher disease THE HOSPITAL FOR SICK CHILDREN (CA) 2012-02-28 US disclosed
US-8124597-B2 Method of treating gaucher disease THE HOSPITAL FOR SICK CHILDREN (CA) 2012-02-28 US disclosed
US-20120021487-A1 METHOD OF TREATING GAUCHER DISEASE MCMASTER UNIVERSITY (CA) 2012-01-26 US disclosed
US-20120021487-A1 METHOD OF TREATING GAUCHER DISEASE MCMASTER UNIVERSITY (CA) 2012-01-26 US disclosed
WO-2009038695-A1 METHOD OF TREATING GAUCHER DISEASE THE HOSPITAL FOR SICK CHILDREN (CA) 2009-03-26 WO disclosed
US-20090075960-A1 Method of treating gaucher disease THE HOSPITAL FOR SICK CHILDREN (CA) 2009-03-19 US disclosed
US-20090075960-A1 Method of treating gaucher disease THE HOSPITAL FOR SICK CHILDREN (CA) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075960-A1 Method of treating gaucher disease GBA1, GAA, GBA3 HSD17B10 791/4885THRB 2527/4885ESR1 4877/4885
US-20200246282-A1 Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase GBA1, GBA3, GAA HSD17B10 1082/4885THRB 3414/4885ESR1 4877/4885
US-10653645-B2 Method for enhancing folding and transport of misfolded glucocerebrosidase GBA1, GBA3, GAA HSD17B10 1082/4885THRB 3414/4885ESR1 4877/4885
US-11160773-B2 Method for enhancing folding and transport of misfolded glucocerebrosidase GBA1, GBA3, GAA HSD17B10 1082/4885THRB 3414/4885ESR1 4877/4885
US-20160113892-A1 Method For Enhancing Folding and Transport of Misfolded Glucocerebrosidase GBA1, GBA3, GAA HSD17B10 1082/4885THRB 3414/4885ESR1 4877/4885
US-20130090388-A1 METHOD OF TREATING GAUCHER DISEASE GBA1, GAA, GBA3 HSD17B10 791/4885THRB 2527/4885ESR1 4877/4885
US-20160331701-A1 Method for Enhancing Folding and Transport of Misfolded Glucocerebrosidase GBA1, GBA3, GAA HSD17B10 1082/4885THRB 3414/4885ESR1 4877/4885
US-10028922-B2 Method for enhancing folding and transport of misfolded glucocerebrosidase GBA1, GBA3, GAA HSD17B10 1082/4885THRB 3414/4885ESR1 4877/4885
US-20130184352-A1 METHOD OF TREATING GAUCHER DISEASE GBA1, GAA, GBA3 HSD17B10 791/4885THRB 2527/4885ESR1 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.